Real-time Euronext Paris 12:35:23 2024-03-28 pm EDT 5-day change 1st Jan Change
3.32 EUR -0.90% Intraday chart for Inventiva -5.14% -18.93%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Inventiva S.A., 2023 Earnings Call, Mar 28, 2024
Inventiva S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ADRs End Flat, Ehang Holdings Ltd. Climbs 15.6% DJ
Transcript : Inventiva S.A. - Special Call
Inventiva: positive results from phase 2 clinical trial CF
Inventiva S.A. Announces Positive Results from the Phase II, Legend, Proof-Of-Concept Study Combining Lanifibranor with Empagliflozin CI
Inventiva: NATiV3 study pause lifted CF
Inventiva Resumes Patient Recruitment for Lanifibranor Clinical Trial MT
Inventiva Announces Voluntary Pause on Screening and Randomization of Its NATiV3 clinical trial CI
ADRs Close Higher, Ambow Education Holding Ltd. Climbs 117.4% DJ
Inventiva Shares Plunge After Halting Recruitment for Clinical Trial NATiV3; Reports Preliminary Revenue MT
Stifel Cuts Price Target on Inventiva to $25 From $27, Maintains Buy Rating MT
Inventiva: share price falls, phase III recruitment suspended CF
Inventiva S.A. Provides Update on its Clinical Trial NATiV3 CI
Inventiva: second tranche drawn from the EIB CF
Inventiva Draws Down EUR25 Million from Loan to Fund Lanifibranor Trial MT
HC Wainwright Adjusts Price Target on Inventiva to $24 From $36, Keeps Buy Rating MT
Inventiva: first randomization in China for NATiV3 CF
Inventiva Says First Person Randomized in China in Phase 3 Trial of Lanifibranor for Nonalcoholic Steatohepatitis MT
Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program CI
Canaccord Genuity Initiates Inventiva at Buy Rating With $12 Price Target MT
Transcript : Inventiva S.A., H1 2023 Earnings Call, Sep 29, 2023
Inventiva S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Inventiva Gains 17% on Licensing Deal for Fatty Liver Disease Drug Candidate in Japan, South Korea MT
Inventiva S.A. and Hepys Pharma, Inc. Announce Exclusive Licensing Agreement to Develop and Commercialize Lanifibranor in Japan and South Korea CI
Chart Inventiva
More charts
Inventiva is a biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. The group is developing two drug candidates - lanifibranor and odiparcil - in non-alcoholic steatohepatitis (« NASH ») and mucopolysaccharidosis (« MPS ») respectively, as well as a portfolio of several programs in the preclinical stage. Lanifibranor, is currently in a pivotal Phase III clinical trial « NATiV3 » for the treatment of patients with NASH and Odiparcil is currently in Phase IIa for the treatment of type VI MPS. As part of Inventiva's decision to focus clinical efforts on the development of Lanifibranor, it suspended clinical efforts relating to Odiparcil and is reviewing available options with respect to its potential further development. Meanwhile, Inventiva is in the process of selecting an oncology drug candidate for the Hippo signaling pathway. Furthermore, the company has established a strategic collaboration with AbbVie, which is currently evaluating Cedirogant (ABBV-157) in a Phase IIb clinical trial. This partnership provides for milestone payments to Inventiva as well as royalties on product sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.32 EUR
Average target price
13.93 EUR
Spread / Average Target
+319.68%
Consensus
  1. Stock
  2. Equities
  3. Stock Inventiva - Euronext Paris
  4. News Inventiva
  5. Inventiva S A : Moving Ahead With Phase III Trial of Prospective Treatment for Liver Disease